Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression

Alan D. Feiger, Robert J. Bielski, James Bremner, Jon F. Heiser, Madhukar Trivedi, Charles S. Wilcox, Douglas L. Roberts, Terry T. Kensler, Robert D. McQuade, Stephen B. Kaplita, Donald G. Archibald

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

The efficacy of nefazodone in prevention of relapse of depression was evaluated in a 36-week double-blind, placebo-substitution, continuation treatment trial. After 16 weeks of acute, single-blind treatment with nefazodone, 131 patients responding to treatment and in stable remission were randomized in a 36-week double-blind trial to either nefazodone (n = 65) or placebo (n = 66). Patients were defined as having relapsed if they had a total score ≥ 18 on the 17-item Hamilton Depression Scale on two consecutive visits or if they discontinued treatment for lack of efficacy. Relapse rates were significantly lower for patients randomized to continued nefazodone treatment than for patients switched to placebo. Kaplan-Meier estimates of relapse rates 9 months (36 weeks) after the end of acute treatment were 1.8% for nefazodone versus 18.3% for placebo (P = 0.009) by the Hamilton Depression Scale and 17.3% versus 32.8% (P = 0.028) by discontinuation for lack of efficacy. The mean modal dose of nefazodone was 412 mg/day at study endpoint. These results demonstrate the clinical effectiveness of up to 1 year's treatment (16 weeks acute and 36 weeks continuation) with nefazodone in depressed patients. Long-term efficacy of nefazodone was accompanied by a good safety profile without any weight gain and with minimal symptoms of withdrawal upon abrupt discontinuation of treatment.

Original languageEnglish (US)
Pages (from-to)19-28
Number of pages10
JournalInternational Clinical Psychopharmacology
Volume14
Issue number1
DOIs
StatePublished - 1999

Fingerprint

Secondary Prevention
Outpatients
Placebos
Depression
Therapeutics
Recurrence
Substance Withdrawal Syndrome
nefazodone
Kaplan-Meier Estimate
Weight Gain
Safety

Keywords

  • Continuation treatment
  • Major depression
  • Nefazodone
  • Placebo
  • Relapse prevention

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression. / Feiger, Alan D.; Bielski, Robert J.; Bremner, James; Heiser, Jon F.; Trivedi, Madhukar; Wilcox, Charles S.; Roberts, Douglas L.; Kensler, Terry T.; McQuade, Robert D.; Kaplita, Stephen B.; Archibald, Donald G.

In: International Clinical Psychopharmacology, Vol. 14, No. 1, 1999, p. 19-28.

Research output: Contribution to journalArticle

Feiger, Alan D. ; Bielski, Robert J. ; Bremner, James ; Heiser, Jon F. ; Trivedi, Madhukar ; Wilcox, Charles S. ; Roberts, Douglas L. ; Kensler, Terry T. ; McQuade, Robert D. ; Kaplita, Stephen B. ; Archibald, Donald G. / Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression. In: International Clinical Psychopharmacology. 1999 ; Vol. 14, No. 1. pp. 19-28.
@article{c75c5812f6914cf08ef0e6e7c59c673c,
title = "Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression",
abstract = "The efficacy of nefazodone in prevention of relapse of depression was evaluated in a 36-week double-blind, placebo-substitution, continuation treatment trial. After 16 weeks of acute, single-blind treatment with nefazodone, 131 patients responding to treatment and in stable remission were randomized in a 36-week double-blind trial to either nefazodone (n = 65) or placebo (n = 66). Patients were defined as having relapsed if they had a total score ≥ 18 on the 17-item Hamilton Depression Scale on two consecutive visits or if they discontinued treatment for lack of efficacy. Relapse rates were significantly lower for patients randomized to continued nefazodone treatment than for patients switched to placebo. Kaplan-Meier estimates of relapse rates 9 months (36 weeks) after the end of acute treatment were 1.8{\%} for nefazodone versus 18.3{\%} for placebo (P = 0.009) by the Hamilton Depression Scale and 17.3{\%} versus 32.8{\%} (P = 0.028) by discontinuation for lack of efficacy. The mean modal dose of nefazodone was 412 mg/day at study endpoint. These results demonstrate the clinical effectiveness of up to 1 year's treatment (16 weeks acute and 36 weeks continuation) with nefazodone in depressed patients. Long-term efficacy of nefazodone was accompanied by a good safety profile without any weight gain and with minimal symptoms of withdrawal upon abrupt discontinuation of treatment.",
keywords = "Continuation treatment, Major depression, Nefazodone, Placebo, Relapse prevention",
author = "Feiger, {Alan D.} and Bielski, {Robert J.} and James Bremner and Heiser, {Jon F.} and Madhukar Trivedi and Wilcox, {Charles S.} and Roberts, {Douglas L.} and Kensler, {Terry T.} and McQuade, {Robert D.} and Kaplita, {Stephen B.} and Archibald, {Donald G.}",
year = "1999",
doi = "10.1097/00004850-199901000-00002",
language = "English (US)",
volume = "14",
pages = "19--28",
journal = "International Clinical Psychopharmacology",
issn = "0268-1315",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression

AU - Feiger, Alan D.

AU - Bielski, Robert J.

AU - Bremner, James

AU - Heiser, Jon F.

AU - Trivedi, Madhukar

AU - Wilcox, Charles S.

AU - Roberts, Douglas L.

AU - Kensler, Terry T.

AU - McQuade, Robert D.

AU - Kaplita, Stephen B.

AU - Archibald, Donald G.

PY - 1999

Y1 - 1999

N2 - The efficacy of nefazodone in prevention of relapse of depression was evaluated in a 36-week double-blind, placebo-substitution, continuation treatment trial. After 16 weeks of acute, single-blind treatment with nefazodone, 131 patients responding to treatment and in stable remission were randomized in a 36-week double-blind trial to either nefazodone (n = 65) or placebo (n = 66). Patients were defined as having relapsed if they had a total score ≥ 18 on the 17-item Hamilton Depression Scale on two consecutive visits or if they discontinued treatment for lack of efficacy. Relapse rates were significantly lower for patients randomized to continued nefazodone treatment than for patients switched to placebo. Kaplan-Meier estimates of relapse rates 9 months (36 weeks) after the end of acute treatment were 1.8% for nefazodone versus 18.3% for placebo (P = 0.009) by the Hamilton Depression Scale and 17.3% versus 32.8% (P = 0.028) by discontinuation for lack of efficacy. The mean modal dose of nefazodone was 412 mg/day at study endpoint. These results demonstrate the clinical effectiveness of up to 1 year's treatment (16 weeks acute and 36 weeks continuation) with nefazodone in depressed patients. Long-term efficacy of nefazodone was accompanied by a good safety profile without any weight gain and with minimal symptoms of withdrawal upon abrupt discontinuation of treatment.

AB - The efficacy of nefazodone in prevention of relapse of depression was evaluated in a 36-week double-blind, placebo-substitution, continuation treatment trial. After 16 weeks of acute, single-blind treatment with nefazodone, 131 patients responding to treatment and in stable remission were randomized in a 36-week double-blind trial to either nefazodone (n = 65) or placebo (n = 66). Patients were defined as having relapsed if they had a total score ≥ 18 on the 17-item Hamilton Depression Scale on two consecutive visits or if they discontinued treatment for lack of efficacy. Relapse rates were significantly lower for patients randomized to continued nefazodone treatment than for patients switched to placebo. Kaplan-Meier estimates of relapse rates 9 months (36 weeks) after the end of acute treatment were 1.8% for nefazodone versus 18.3% for placebo (P = 0.009) by the Hamilton Depression Scale and 17.3% versus 32.8% (P = 0.028) by discontinuation for lack of efficacy. The mean modal dose of nefazodone was 412 mg/day at study endpoint. These results demonstrate the clinical effectiveness of up to 1 year's treatment (16 weeks acute and 36 weeks continuation) with nefazodone in depressed patients. Long-term efficacy of nefazodone was accompanied by a good safety profile without any weight gain and with minimal symptoms of withdrawal upon abrupt discontinuation of treatment.

KW - Continuation treatment

KW - Major depression

KW - Nefazodone

KW - Placebo

KW - Relapse prevention

UR - http://www.scopus.com/inward/record.url?scp=0032929381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032929381&partnerID=8YFLogxK

U2 - 10.1097/00004850-199901000-00002

DO - 10.1097/00004850-199901000-00002

M3 - Article

C2 - 10221638

AN - SCOPUS:0032929381

VL - 14

SP - 19

EP - 28

JO - International Clinical Psychopharmacology

JF - International Clinical Psychopharmacology

SN - 0268-1315

IS - 1

ER -